Trial Profile
An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; SLC 0111 (Primary)
- Indications Adenocarcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Adverse reactions
- 02 Aug 2023 Planned End Date changed from 1 Dec 2024 to 1 Aug 2025.
- 02 Aug 2023 Planned primary completion date changed from 1 Jul 2024 to 1 Feb 2025.
- 02 Aug 2023 Status changed from suspended to recruiting.